Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MediciNova, Inc. - Common Stock (NQ: MNOV ) 2.070 +0.120 (+6.15%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 27,964 Open 2.030 Bid (Size) 1.990 (3) Ask (Size) 2.150 (1) Prev. Close 1.950 Today's Range 2.030 - 2.139 52wk Range 1.120 - 2.550 Shares Outstanding 49,046,246 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND December 05, 2024 From MediciNova, Inc. Via GlobeNewswire This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday December 02, 2024 Via Benzinga Performance YTD +25.45% +25.45% 1 Month +2.99% +2.99% 3 Month +8.38% +8.38% 6 Month +43.75% +43.75% 1 Year +46.81% +46.81% More News Read More MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders November 19, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver November 14, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis November 11, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 24, 2024 Via Benzinga MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) October 23, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session October 11, 2024 Via Benzinga MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) September 30, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND September 09, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting September 03, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition August 29, 2024 From MediciNova, Inc. Via GlobeNewswire Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024 August 19, 2024 Via InvestorPlace MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations June 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer June 05, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 June 03, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions May 28, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer May 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 14, 2024 From MediciNova, Inc. Via GlobeNewswire MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 May 10, 2024 Via InvestorPlace MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 07, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session April 05, 2024 Via Benzinga MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) April 02, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 27, 2024 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
